TARE FOR COLORECTAL LIVER METASTASES:
THE SIRFLOX AND FOXFIRE TRIALS
What the three Phase III trials of Y-90 + chemotherapy for colorectal liver metastases showed โ who benefits most, what the evidence supports, and how TARE fits into the CRLM management algorithm.
analyticsAt a Glance
- check_circleSIRFLOX demonstrated a 7.9-month improvement in liver progression-free survival with SIR-Spheres + FOLFOX vs FOLFOX alone
- check_circleFOXFIRE Global pooled analysis showed OS benefit in liver-only metastatic colorectal cancer subgroup
- check_circleResponse rate improvements with SIR-Spheres addition may increase resectability of initially unresectable liver metastases
- check_circleCancerFax coordinates TARE for CRLM at specialist centres in China and India
Why TARE Is Relevant in Colorectal Liver Metastases
Colorectal cancer metastasises to the liver in approximately 50โ60% of patients โ and in many cases, the liver is the dominant or only site of metastatic disease. When systemic chemotherapy alone fails to achieve resectability or adequate disease control, liver-directed therapy offers an additional treatment dimension. TARE (Y-90 SIR-Spheres) combined with first-line FOLFOX has the largest randomised trial base of any liver-directed therapy in CRLM.
โFor CRLM patients with liver-dominant or liver-only disease, TARE adds a locoregional dimension to systemic chemotherapy that no oral drug or IV infusion can replicate.โ
Liver-Only vs Liver-Dominant Disease
The clinical benefit of TARE in CRLM is most pronounced in patients with liver-only or liver-dominant disease โ where the liver is the primary determinant of survival. In patients with extensive extrahepatic disease, systemic chemotherapy for overall disease control is the priority and liver-directed therapy adds less incremental benefit.
Resectability Conversion
One of the most clinically valuable applications of TARE in CRLM is converting initially unresectable patients to resectable โ by achieving sufficient tumour downsizing through the combined effect of FOLFOX + liver-directed radiation. Increased liver objective response rate directly correlates with improved resection rates.
SIRFLOX, FOXFIRE, and FOXFIRE Global โ Trial Results
The three Phase III trials of SIR-Spheres + FOLFOX vs FOLFOX alone in first-line CRLM โ the definitive prospective evidence base for Y-90 radioembolization in colorectal liver metastases.
SIRFLOX: SIR-Spheres + mFOLFOX6 vs mFOLFOX6 (First-Line CRLM)
Primary endpoint: PFS from randomisation. SIR-Spheres added to first-line mFOLFOX6 ยฑ bevacizumab. Source: van Hazel et al., JCO 2016.
- Median PFS (liver): SIR-Spheres + FOLFOX20.5 months
- Median PFS (liver): FOLFOX alone12.6 months
- Overall response rate: SIR-Spheres + FOLFOX76.4%
- Overall response rate: FOLFOX alone68.1%
FOXFIRE Global: Pooled Analysis โ Liver-Only Metastases Subgroup
Pooled analysis of SIRFLOX, FOXFIRE, and FOXFIRE Global โ pre-specified subgroup of patients with liver-only metastases. Source: Sharma et al., Ann Oncol 2021.
- Median OS: SIR-Spheres + chemo (liver-only subgroup)22.0 months
- Median OS: chemo alone (liver-only subgroup)17.1 months
TARE for CRLM โ Patient Selection Framework
Based on the pooled Phase III data, these are the patient characteristics that define who benefits most from adding TARE to first-line chemotherapy in colorectal liver metastases.
| Patient Factor | Favours Adding TARE | Neutral / Less Clear Benefit | Against Adding TARE |
|---|---|---|---|
| Metastatic pattern | Liver-only or liver-dominant disease | Liver + limited lung metastases | Extensive multisite extrahepatic disease |
| Resectability intent | Conversion to resectability is the goal | Stable disease control is the goal | Palliative intent only, poor PS |
| Timing | First-line (alongside FOLFOX) โ primary evidence | Second-line rescue in liver progression | After โฅ3 prior lines โ limited evidence |
| RAS mutation status | RAS mutant (may benefit more in pooled subgroups) | RAS wild-type | N/A โ both can receive TARE |
| Number of liver lesions | Multiple bilateral lesions unsuitable for ablation | Few bilateral lesions | Solitary resectable lesion โ resect directly |
| ECOG PS | 0โ1 | 2 | 3โ4 |
Adding TARE to Chemotherapy โ What the Evidence Covers and What It Doesn't
The SIRFLOX/FOXFIRE data covers a specific clinical scenario โ first-line FOLFOX + SIR-Spheres. Understanding what the evidence does and does not support is important for clinical decision-making.
Evidence Supports
- SIR-Spheres + FOLFOX in first-line CRLMThe definitive evidence base โ three Phase III trials with 1,100+ patients. Liver PFS benefit and OS benefit in liver-only subgroup are established.
- Liver-only metastases subgroup benefitThe pre-specified subgroup analysis from FOXFIRE Global shows the clearest OS benefit (22 vs 17.1 months) โ these patients should be considered for TARE discussion.
- Resectability conversion strategyHigher ORR with TARE addition supports its role in conversion to resection strategies โ improved liver response rate โ more patients proceeding to hepatectomy.
- TheraSphere in CRLMWhile SIRFLOX/FOXFIRE used SIR-Spheres, TheraSphere is used for CRLM at many centres based on institutional experience โ evidence is less formalised but results are broadly comparable.
Not Well-Evidenced
- TARE + FOLFIRI or FOLFOXIRILimited trial data for TARE combined with irinotecan-based first-line regimens โ SIRFLOX specifically used FOLFOX.
- TARE + bevacizumab/cetuximab/panitumumabBiologic addition to TARE + chemotherapy combinations has limited prospective data โ bevacizumab was allowed in SIRFLOX but subgroup analysis is underpowered.
- TARE in MSI-H CRLM patients on pembrolizumabThe interaction between Y-90 and checkpoint inhibitor therapy in CRLM has not been prospectively studied โ this combination is theoretically interesting but empirically untested.
- TARE after KRAS G12C inhibitor failure in CRLMNo specific data for TARE in the context of prior KRAS G12C-targeted therapy โ applies to novel targeted therapy combinations more broadly.
TARE for CRLM โ Key Numbers From Phase III Data
The headline clinical trial figures from the SIRFLOX/FOXFIRE programme.
- +7.9 monthsLiver-PFS improvement: SIR-Spheres + FOLFOX vs FOLFOX alone (SIRFLOX)A 7.9-month improvement in liver progression-free survival โ the most robust outcome from the SIRFLOX primary analysis.
- +4.9 monthsOS improvement in liver-only subgroup (FOXFIRE Global pooled analysis)22.0 vs 17.1 months โ the pre-specified subgroup where TARE addition had the clearest survival benefit, guiding current patient selection.
- 76.4%Overall response rate with SIR-Spheres + FOLFOX (SIRFLOX)vs 68.1% with FOLFOX alone โ the higher ORR supports TARE's role in resectability conversion for initially unresectable CRLM.
More from the TARE / Y-90 Resource Library
Continue exploring Y-90 radioembolization โ from the HCC evidence base to the complete treatment guide.
Frequently Asked Questions: TARE for Colorectal Liver Metastases
Why didn't SIRFLOX show an OS benefit if liver PFS improved so dramatically?
The SIRFLOX primary analysis showed significant liver PFS benefit but not OS benefit โ a finding that puzzled many clinicians. The explanation relates to extrahepatic progression: TARE controls liver disease, but patients who progressed extraheptic (outside the liver) died from systemic disease regardless of liver control. In patients with liver-only disease, where liver progression is the primary survival driver, the OS benefit does emerge โ as seen in the FOXFIRE Global pre-specified liver-only subgroup analysis (+4.9 months OS). This subgroup finding guides current patient selection: liver-dominant and liver-only patients benefit most.
Can TARE be used alongside bevacizumab for CRLM?
Bevacizumab was allowed in SIRFLOX (up to 60% of patients received it) but the subgroup analysis for bevacizumab vs non-bevacizumab is underpowered. In clinical practice, TARE + FOLFOX + bevacizumab is used at some expert centres without a clear signal of additive toxicity, but no dedicated trial has specifically addressed this combination. CancerFax can identify Chinese centres experienced in TARE + chemotherapy + bevacizumab combinations for CRLM.
How many CRLM lesions can TARE treat in a single session?
TARE distributes through the hepatic arterial tree โ targeting all lesions within the treated territory regardless of number. A lobar TARE covers all lesions in the right or left liver lobe in one session. Bilobar disease is treated in two sequential sessions (typically 4โ6 weeks apart โ right lobe first, then left lobe). There is no practical limit to the number of lesions treated per TARE session, unlike thermal ablation which is limited to 3โ4 lesions per session. This makes TARE particularly valuable for patients with numerous bilateral CRLM not amenable to ablation.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Has Your Colorectal Cancer Spread to the Liver?
CancerFax reviews your CRLM records โ number and size of lesions, prior chemotherapy, RAS/BRAF status, and resectability assessment โ to identify whether TARE as an addition to chemotherapy is evidence-supported for your case.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist and interventional radiologist before making treatment decisions.